Direct Biologics Announces Publication of Significant Survival Benefit with ExoF

Direct Biologics LLC, a biotechnology company in the late stages of development, has recently published groundbreaking findings from their Phase 2 clinical trial in the prestigious Journal CHEST. The trial focused on evaluating the effectiveness of ExoFlo™, a regenerative medicine platform that utilizes extracellular vesicles (EVs) derived from bone marrow-derived mesenchymal stem cells (BM-MSCs..